Global Female Sexual Dysfunction Treatment Market 2019-2023 | Increasing Use of Drugs Causing Sexual Dysfunctions in Women to Boost Market Growth | Technavio

Technavio has published a new market research report on the global female sexual dysfunction treatment market from 2019-2023. (Graphic: Business Wire)

LONDON--()--The global female sexual dysfunction treatment market is expected to post a CAGR close to 37% during the period 2019-2023, according to the latest market research report by Technavio.

A key factor driving the growth of the market is the increasing prevalence of chronic diseases. Sexual dysfunctions are common in women and involve loss of desire, orgasm problems, and pain during sex. The onset of sexual dysfunctions in women is attributed to hormonal factors, menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive. Female sexual dysfunctions can be caused due to various chronic diseases such as diabetes. Patients with diabetes may have several clinical conditions, including overweight, hypertension, metabolic syndrome, and atherogenic dyslipidemia, which are risk factors for sexual dysfunction in women. Therefore, rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of women having sexual dysfunctions, which, in turn, will drive the growth of the global female sexual dysfunction treatment market during the forecast period.

As per Technavio, the increasing use of drugs causing sexual dysfunctions in women will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global female sexual dysfunction treatment market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global female sexual dysfunction treatment market: Increasing use of drugs causing sexual dysfunctions in women

There are several classes of drugs such as antidepressants, antipsychotics, antiepileptics, and contraceptives, which result in sexual dysfunction in women. Hypertension is associated with sexual dysfunction and is more common in women. Drugs such as beta blockers decrease sexual desire in women. Alpha-adrenergic drugs also reduce sexual desire and arousal in women. Similarly, antidepressants drugs cause sexual difficulties. Furthermore, the majority of sexual dysfunction is caused by dopamine receptor blockade. This causes hyperprolactinemia with subsequent suppression of the hypothalamic-pituitary-gonadal axis and hypogonadism in women resulting in decreased sexual desire, impaired arousal, and orgasm. In addition, drugs used in the treatment of epilepsy, such as gabapentin and topiramate, have been associated with orgasmic dysfunction and reduced libido in women. Thus, the use of such drugs will increase the incidences of sexual dysfunctions in women, thereby increasing the demand for drugs to treat sexual dysfunctions in women.

“Apart from the increasing use of drugs causing sexual dysfunctions in women, the growing awareness of female sexual dysfunction, the approval and availability of drug to treat hypoactive sexual desire disorder, and the increasing R&D for treatment of sexual dysfunction in women are some other major aspects that are expected to boost market growth during the forecast period,” says a senior analyst at Technavio.

Global female sexual dysfunction treatment market: Segmentation analysis

This market research report segments the global female sexual dysfunction treatment market by type (non-hormonal therapy and hormonal therapy) and geographical regions (North America, Europe, Asia and ROW).

The North American region led the market in 2018, followed by Europe, Asia and ROW respectively. During the forecast period, the North American region is expected to maintain its dominance over the global market and register the highest incremental growth due to increasing prevalence of chronic diseases in the region.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

The global female sexual dysfunction treatment market is expected to post a CAGR close to 37% during the period 2019-2023, according to Technavio.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com